Back to results
US 11,813,298 B2Granted
Oncolytic poliovirus for human tumors
AssigneeDuke University
InventorsMatthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
Life of this patent
Estimating the term…
Abstract
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
Claims18
A method for treating a human patient having a melanoma tumor, the method comprising:
- administering by directly injecting into the melanoma tumor a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus's 5′ untranslated region between the poliovirus's cloverleaf and the poliovirus's open reading frame.
A method for treating a human patient having a head and neck tumor, the method comprising:
- administering by directly injecting into the head and neck tumor a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus's 5′ untranslated region between the poliovirus's cloverleaf and the poliovirus's open reading frame.
A method for treating a human patient having a bladder tumor, the method comprising:
- administering directly to the bladder tumor a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus's 5′ untranslated region between the poliovirus's cloverleaf and the poliovirus's open reading frame.
Dependencies are inferred from the claim text.